Ron Laethem, Ph.D., Joins Qualyst Transporter Solutions, LLC. Qualyst continues to expand ADME capabilities
Durham, N.C. (August 09, 2017) – Dr. Ron Laethem joined Qualyst Transporter Solutions, LLC as a senior scientist to lead ADME services. His focus includes study design and scientific oversight of Qualyst’s capabilities for in vitro drug-drug interaction (DDI) studies to provide in vivo-relevant data suitable for regulatory filings.
“I am excited to be joining the team at Qualyst,” said Dr. Laethem. “Qualyst’s sandwich-cultured human hepatocyte model using Transporter Certified™ hepatocytes creates more in vivo-relevant conditions compared to conventional, transporter-deficient models.”
Chris Black, Qualyst CEO, commented, “We are thrilled to have Ron on board. We are committed to providing excellence in ADME services and Ron adds to our deep bench of scientific expertise. We know our clients will benefit from the opportunity to work with Ron.”
Dr. Laethem is a drug metabolism scientist with 25 years’ experience in the biopharmaceutical industry with expertise in in vitro ADME research. He has developed better in vitro ADME research methods, led projects to improve the quality of data obtained from in vitro ADME assays, and is skilled in interpreting in vitro ADME data to better inform drug discovery and development decisions.
Dr. Laethem comes to Qualyst from QPS Hepatic Biosciences where he was an Associate Director heading up the site located in RTP. He oversaw the daily business operations of the site and acted as the test facility manager for all in vitro studies carried out there. Ron joined QPS in 2012 as a Senior Principal Scientist. Prior to joining QPS, he served as the Senior Director of R&D at Triangle Research Labs, LLC, starting up and overseeing the company’s in vitro ADME contract research group. Prior to this Ron spend eight years at BD Technologies working on improved in vitro tools for ADME scientists. Ron was one of the founders of HepatoTech, Inc. that was later acquired by CellzDirect. Ron began his career at GSK and spent nine years there working on developing and implementing new in vitro ADME tools and serving on project teams contributing to CYP induction and inhibition issues with lead and candidate compounds.
Dr. Laethem obtained his Ph.D. in biology from Case Western Reserve University and while there also began his postdoctoral work under an NIH Metabolism Training Grant. He obtained his B.S. in biology from Adrian College in Adrian Michigan.
About Qualyst Transporter Solutions, LLC
Qualyst Transporter Solutions, LLC (Qualyst) provides in vitro hepatic models to predict the effect of drugs and other compounds on the human liver. Qualyst’s in vitro models integrate hepatic uptake, metabolism, regulation, and efflux and demonstrate superior in vitro-in vivo correlation compared to conventional systems. Qualyst’s proprietary technology, products, and services are used by leading pharmaceutical, nutrition, cosmetics and consumer products, and chemical companies to provide clinically-relevant answers to liver-related questions, and to address regulatory concerns about their products.